Naphthylpropylaminopentane
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1-(2-Naphthyl)-2-propylaminopentane (NPAP), also known as 2-naphthyl-α,N-dipropylphenethylamine, is a monoaminergic activity enhancer (MAE) of the α-propylphenethylamine and naphthylaminopropane families related to phenylpropylaminopentane (PPAP).[1] It is the analogue of PPAP in which the phenyl ring has been replaced with a naphthalene ring.[1] MAEs are agents that enhance the action potential-mediated release of monoamine neurotransmitters.[2][3][4] NPAP is a MAE of norepinephrine and dopamine but not of serotonin.[1] Its potency is similar to that of PPAP.[1] As with PPAP, the (â)-enantiomer of NPAP is more potent as a MAE.[1] Like PPAP, it is inactive as a classical monoamine releasing agent.[1] NPAP was developed by József Knoll and colleagues and was first described in 2001.[1]
- None
| Clinical data | |
|---|---|
| Other names | 1-(2-Naphthyl)-2-propylaminopentane; NPAP; 2-Naphthyl-α,N-dipropylphenethylamine |
| Drug class | Monoaminergic activity enhancer |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H25N |
| Molar mass | 255.405 g·molâ1 |
| 3D model (JSmol) | |
| |
| |
See also
- Substituted naphthylethylamine
- Substituted α-propylphenethylamine
- Methylenedioxyphenylpropylaminopentane (MPAP)
- Benzofuranylpropylaminopentane (BPAP)
- Indolylpropylaminopentane (IPAP)
- Naphthylaminopropane
- Ethylnaphthylaminopropane
- Naphyrone (naphthylpyrovalerone)
- Ethylnaphthidate (HDEP-28)
- Methylnaphthidate (HDMP-28)